Mind Medicine (MindMed) Inc. today announced that the U.S. Food and Drug Administration has placed a clinical hold on its IND submission intended to support the initiation of a Phase 2b trial of lysergic acid diethylamide (LSD) for the treatment of generalized anxiety disorder (GAD).
Category Press Release
Country United States of America
Companies Featured
MindMedMindMed is one of the largest companies in the psychedelics space and is developing various psychedelics for mental health disorders.
?>